Vous trouverez plus d’informations scientifiques et
d’études (en anglais) dans la base de l’IACM : Database on Clinical Studies and Case Reports
·
Amélioration
des symptômes ou évaluation positive par les auteurs
o
Aucune
amélioration significative des symptômes ou évaluation négative par les auteurs
v
Détérioration
des symptômes
Sommaire
Nausées et vomissements
- chimiothérapie anticancéreuse
Nausées et
vomissements - radiothérapie
Nausées et vomissements - métastases
Nausées et vomissements - chirurgie
Nausées et vomissements - VIH/sida
Nausées et vomissements - traitement de l'hépatite C
Nausées et vomissements - grossesse
Nausées et
vomissements – Mal du transport
Nausées et vomissements - autres
Nausées et vomissements - sujets sains
Perte de l'appétit - maladie d'Alzheimer
Perte de l'appétit - gériatrie
Perte de l'appétit - anorexie mentale
Perte de l'appétit -
sujets sains
Spasticité - sclérose en plaques
Spasticité - traumatisme médullaire
Spasticité
- origines diverses
Douleurs - douleurs chroniques, neuropathiques/sclérose en
plaques
Douleurs - douleurs
chroniques, cancer
Douleurs - douleurs chroniques
Douleurs - douleurs
aiguës, chirurgie
Douleurs - douleurs aiguës, sujets sains
Sclérose
latérale amyotrophique / SLA
Dyskinésie causée par la lévodopa (dyskinésie tardive)
Syndrome de Gilles de la Tourette, tics
Désordre du
mouvement Hyperkinétique
Trouble Déficit de l’Attention / Hyperactivité (TDAH)
Trouble
obsessionnel compulsif / TOC
Glaucome /
Pression intraoculaire
Pression intraoculaire -
sujets sains
Bronchodilatation
- sujets sains
COPD (Maladie pulmonaire obstructrice chronique)
Hypertension
/ pression sanguine
Trouble du stress post-traumatique (PTSD)
Dépendance à la cocaïne / crack
·
Artim R,
DiBella N. Tetrahydrocannabinol (THC) plus prochlorperazine (PCZ) for
refractory nausea and vomiting (N/V). Proceedings
of the American Society for Clinical Oncology 1983;2:84.
·
Chang AE,
Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I.
Delta-9-tetrahydrocannabinol as an antiemetics in cancer patients receiving
high-dose methotrexate. Annals of Internal Medicine 1979;91:819-824.
o
Chang AE,
Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, Rosenberg SA.. A
prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in
patients receiving adriamycin and cytoxan chemotherapy. Cancer 1981; 47: 1746-1751.
·
Colls BM,
Ferry DG, Gray AJ, Harvey VJ, McQueen EG. The antiemetic activity of
tetrahydrocanabinol versus metoclopramide and thiethylperazine in patients
undergoing cancer chemotherapy. New Zealand Medical Journal 1980;91:449-451.
·
Ekert H,
Waters KD, Jurk KH, Mobilia J, Loughnan P. Ameriloration of cancer chemotherapy-induced
nausea and vomiting by delta-9-tetrahydrocannabinol. Medical Journal of
Australia 1979;2:657-659.
·
Frytak S,
Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connnell MJ.
Delta-9-tetrahydrocannabinol as an antiemetics for patients receiving cancer
chemotherapy. A comparison with prochlorperazine and a placebo. Annals of
Internal Medicine 1979;91:825-830.
·
Gralla
RJ, Tyson LB, Bordin LA, Clark RA, Kelsen DP, Kris MG. Antiemetic therapy: a
review of recent studies and a report of a random assignment trial comparing
metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treatment Report
1984;68:163-172.
·
Kluin-Nelemans JC, Nelemans FA, Meuwissen
OJATh, Maes RAA. D9-tetrahydrocannabinol
(THC) as an antiemetic in patients treated with cancer chemotherapy; a
double-blind cross-over trial against placebo. Veterinary and Human Toxicology
1979;21:338-340.
·
Lane M,
Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J. Dronabinol and
prochlorperazine in combination for treatment of cancer chemotherapy-induced
nausea and vomiting. Journal of Pain and Symptom Management 1991;6:352-359.
·
Levitt M,
Faiman C, Hawks R, Wilson A. Randomized double blind comparison of
delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy antiemetics.
Proceedings of the American Society for Clinical Oncology 1984;3:91.
·
Levitt M,
Wilson A, Bowman D, Faiman C, Kemel S, Krepart G. Dose vs response of
tetrahydroannabinol (THC) vs prochlorperazine as chemotherapy antiemetics.
Proceedings of the American Society for Clinical Oncology 1981;22:422.
·
McCabe M,
Smith FP, Goldberg D, Macdonald J, Woolley PV, Warren R. Efficacy of
tetrahydrocannabinol in patients refractory to standard anti-emetic therapy.
Investigational New Drugs 1988;6:243-246.
·
Neidhart
JA, Gagen MM, Wilson HE, Young DC. Comparative trial of the antiemetic effects
of THC and haloperidol. International
Journal of Clinical Pharmacology Research 1981; 21: 38-42S.
·
Orr LE,
McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol. Compared with
placebo and prochlorperazine in chemotherapy-associated nausea and emesis.
Archives of Internal Medicine 1980;140:1431-433.
·
Sallan SE,
Cronin C, Zelen M, Zinberg NE. Antiemetics
in patients receiving chemotherapy for cancer. A randomized comparison of
delta-9-tetrahydrocannabinol and prochlorperazine. New England Journal of
Medicine 1980;302:135-138.
·
Sallan
SE, Zinberg NE, Frei E. Antiemetic effect of delta-9-tetrahydrocannabinol in
patients receiving cancer chemotherapy. New England Journal of Medicine
1975;293:795-797.
·
Ungerleider
JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and
cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine.
Cancer 1982;50:636-645.
·
Ungerleider
JT, Sarna G, Fairbanks LA, Goodnight J, Andrysiak T, Jamison K. THC or
compazine for the cancer chemotherapy patient - the UCLA study. Part II:
patient drug preference. American Journal of Clinical Oncology 1985; 8:
142-147.
·
Meiri E,
Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, Baranowski V.
Efficacy of dronabinol alone and in combination with ondansetron versus
ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr
Med Res Opin 2007;23(3):533-43.
·
Levitt M,
Faiman C, Hawks R, Wilson A. Randomized double blind comparison of
delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy antiemetics.
Proceedings of the American Society for Clinical Oncology 1984;3:91.
·
Duran M,
Pérez E, Abanades S, Vidal X, Saura C, Majem M, Arriola E, Rabanal M, Pastor A,
Farré M, Rams N, Laporte JR, Capellà D. Preliminary efficacy and safety of an
oromucosal standardized cannabis extract in chemotherapy-induced nausea and
vomiting. Br J Clin Pharmacol 2010;70(5):656-63.
·
Ahmedzai
S, Carlyle DL, Clader IT, Moran F. Anti-emetic efficacy and toxicity of
nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. British Journal
of Cancer 1983;48:657-663.
·
Chan HS,
Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer
chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987; 79: 946-952
·
Crawford
SM, Buckman R. Nabilone and metoclopramide in the treatment of nausea and
vomiting due to cisplatinum: a double blind study. Medical Oncology and Tumor Pharmacotherapy 1986; 3: 39-42.
·
Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW,
Adams L, Sneddon M, et al. A randomized trial of oral nabilone and
prochlorperazine compared to intravenous metoclopramide and dexamethasone in
the treatment of nausea and vomiting induced by chemotherapy regimens
containing cisplatin or cisplatin analogues. European Journal of Cancer and
Clinical Oncology 1988; 24: 685-689.
·
Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: An alternative antiemetic for cancer chemotherapy. Archives of
Disease in Childhood 1986;61:502-505.
·
Einhorn
LH, Nagy C, Furnas B, Williams SD. Nabilone: an effective antiemetic in
patients receiving cancer chemotherapy. Journal of Clinical Pharmacology. 1981
Aug-Sep;21(8-9 Suppl):64S-69S.
·
George M,
Pejovic MH, Thuaire M, Kramar A, Wolff JP. Randomized comparative trial of a
new anti-emetic: nabilone, in cancer patients treated with cisplatin. Biomedicine and Pharmacotherapy 1983;
37: 24-27.
·
Herman TS, Einhorn LH, Jones SE, Nagy C,
Chester AB, Dean JC, et al. Superiority
of nabilone over prochlorperazine as an antiemetic in patients receiving cancer
chemotherapy. New England Journal of
Medicine 1979; 300: 1295-1297.
·
Johansson
R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs
prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treatment Reviews 1982; 9:
25-33.
·
Jones SE,
Durant JR, Greco FA, Robertone A. A multi-institutional phase III study of
nabilone vs placebo in chemotherapy-induced nausea and vomiting. Cancer Treatment Reviews 1982; 9:
45-48
·
Levitt M.
Nabilone vs placebo in the treatment of chemotherapy-induced nausea and
vomiting in cancer patients. Cancer
Treatment Reviews 1982; 9(suppl B): 49-53.
·
Nagy CM,
Furnas BE, Einhorn LH, Bond WH. Nabilone: antiemetic crossover study in cancer
chemotherapy patients. Proceedings of the American Society for Cancer Research
1978;19:30.
·
Niederle N, Schutte J, Schmidt CG. Crossover comparison of the antiemetic efficacy of nabilone and
alizapride in patients with nonseminomatous testicular cancer receiving
cisplatin therapy. Klinische
Wochenschrift 1986; 64: 362-365.
·
Niiranen
Aila, Mattson K. A cross-over comparison of nabilone and prochlorperazine for
emesis induced by cancer chemotherapy. American Journal of Clinical Oncology
1985;8:336-340.
·
Pomeroy
M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone
versus domperidone in the treatment of cytotoxic-induced emesis. Cancer
Chemotherapy and Pharmacology 1986;17:285-288.
·
Priestman
SG, Priestman TJ, Canney PA. A double-blind randomised cross-over comparison of
nabilone and metoclopramide in the control of radiation-induced nausea. Clinical Radiology 1987; 38: 543-544.
·
Steele N,
Gralla RJ, Braun Jr DW, Young CW. Double-blind comparison of the antiemetic
effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treatment Report 1980;
64: 219-224.
·
Wada JK,
Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE. Double-blind, randomized,
crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treatment Reviews 1982;
9(Suppl B): 39-44
·
Citron
ML, Herman TS, Vreeland F, Krasnow SH, Fossieck BE, Jr. Antiemetic efficacy of
levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced
nausea and vomiting. Cancer Treatment Reports 1985;69:109-112.
·
Higi M, Niederle N, Bremer K, Schmitt G,
Schmidt CG, Seeber S. Levonantradol bei der Behandlung von zytostatika-bedingter
Übelkeit und Erbrechen. Deutsche
Medizinische Wochenschrift 1982; 107: 1232-1234.
·
Hutcheon
AW, Palmer JB, Soukop M, Cunningham D, McArdle C, Welsh J, et al. A randomised multicentre single blind comparison of a cannabinoid
anti-emetic (levonantradol) with ychlorpromazine in patients receiving their
first cytotoxic chemotherapy. European
Journal for Cancer and Clinical Oncology 1983; 19: 1087-1090
·
Stambaugh
Jr JE, McAdams J, Vreeland F. Dose ranging evaluation of the antiemetic
efficacy and toxicity of intramuscular levonantradol in cancer subjects with
chemotherapy-induced emesis. International
Journal of Clinical Pharmacology Research1984; 24: 480-485
·
Abrahamov
A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in
pediatric oncology. Life Sciences 1995;56:2097-2102.
·
Vinciguerra
V, Moore T, Brennan E. Inhalation marijuana as an antiemetic for cancer
chemotherapy. New York State Journal of Medicine 1988;88:525-527.
·
Musty RE,
Rossi R. Effects of smoked cannabis and oral delta-9-tetrahydrocannabinol on
nausea and emesis after cancer chemotherapy: A review of state clinical trials.
J Cannabis Ther 2001;1(1):29-42.
·
Doblin
RE, Kleiman MA. Marijuana as
antiemetic medicine: a survey of oncologists' experiences and attitudes. American Journal of Clinical Oncology
1991; 9: 1314-1319.
o
Schwartz
RH, Voth EA, Sheridan MJ. Marijuana to prevent nausea and vomiting in cancer
patients: a survey of clinical oncologists. South Medical Journal
1997;90(2):167-72.
·
Ungerleider
JT, Andrysiak TA, Fairbanks LA, Tesler AS, Parker RG. Tetrahydrocannabinol vs.
prochlorperazine. The effects of two antiemetics on patients undergoing
radiotherapy. Radiology 1984;150(2):598-9.
·
Lucraft
HH, Palmer MK. Randomised clinical trial of levonantradol and chlorpromazine in
the prevention of radiotherapy-induced vomiting. Clinical
Radiology 1982; 33: 621-622.
·
Zutt M,
Hanssle H, Emmert S, Neumann C, Kretschmer L. [Dronabinol for supportive
therapy in patients with malignant melanoma and liver metastases] [Article in
German]. Hautarzt 2006;57(5):423-7.
·
Gonzalez-Rosales
F, Walsh D. Intractable nausea and vomiting due to gastrointestinal mucosal
metastases relieved by tetrahydrocannabinol (dronabinol). Journal of Pain and
Symptom Management 1997;14(5):311-314.
·
Layeeque
R, Siegel E, Kass R, Henry-Tillman RS, Colvert M, Mancino A, Klimberg VS. Prevention of nausea and vomiting following breast surgery. Am J Surg
2006;191(6):767-72.
·
Lewis IH,
Campbell DN, Barrowcliffe MP. Effect of nabilone on nausea and vomiting after
total abdominal hysterectomy. British
Journal of Anaesthesia 1994; 73: 244-246.
·
de Jong BC, Prentiss D, McFarland W,
Machekano R, Israelski DM. Marijuana
use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe
nausea. J Acquir Immune Defic Syndr 2005;38(1):43-6.
·
Woolridge
E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV
for pain and other medical symptoms. J Pain Symptom Manage 2005;29(4):358-67.
·
Sidney S.
Marijuana use in HIV-positive and AIDS patients: Results of a an anonymous mail
survey. J Cannabis Ther 2001;1(3-4):35-43.
·
Corless
IB, Lindgren T, Holzemer W, Robinson L, Moezzi S, Kirksey K, Coleman C, Tsai
YF, Sanzero Eller L, Hamilton MJ, Sefcik EF, Canaval GE, Rivero Mendez M,
Kemppainen JK, Bunch EH, Nicholas PK, Nokes KM, Dole P, Reynolds N. Marijuana
Effectiveness as an HIV Self-Care Strategy. Clin Nurs Res 2009;18(2):172-93.
·
Costiniuk
CT, Mills E, Cooper CL. Evaluation of oral cannabinoid-containing medications for
the management of interferon and ribavirin-induced anorexia, nausea and weight
loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol
2008;22(4):376-80.
·
Sylvestre
DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological
outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol
2006;18(10):1057-63.
·
Curry
W-NL. Hyperemesis gravidarum and clinical cannabis: To eat or not to eat? J
Cannabis Ther 2002;2(3-4):63-83.
·
Westfall
RE, Janssen PA, Lucas P, Capler R. Survey of medicinal cannabis use among
childbearing women: patterns of its use in pregnancy and retroactive
self-assessment of its efficacy against 'morning sickness'. Complement Ther
Clin Pract 2006;12(1):27-33.
·
Choukèr A, Kaufmann I, Kreth S, Hauer D,
Feuerecker M, Thieme D, Vogeser M, Thiel M, Schelling G. Motion
sickness, stress and the endocannabinoid system. PLoS One 2010;5(5):e10752.
·
Merriman
AR, Oliak DA. Use of medical
marijuana for treatment of severe intractable nausea after laparoscopic
Roux-en-Y gastric bypass surgery: case report. Surg Obes Relat Dis, 26 January
2008 [Electronic publication ahead of print])
·
Soderpalm
AH, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana: subjective
and behavioral effects on nausea induced by syrup of ipecac. Pharmacology,
Biochemistry and Behavior
2001;69(3-4):343-50.
·
Beal JE, Olson R, Laubenstein L, Morales JP,
Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV. Dronabinol as a treatment for anorexia associated with weight loss in
patients with AIDS. Journal of Pain and Symptom Management 1995;10(2):89-97.
·
Timpone
JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, Galetto G, and the DATRI
004 Study Group. The safety and pharmacokinetics of single-agent and
combination therapy with megestrol acetate and dronabinol for the treatment of
HIV wasting syndrome. AIDS Research and Human Retroviruses 1997;13:305-315.
·
Abrams
DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt
BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune
JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1
infection: a randomized,
placebo-controlled clinical trial. Ann Intern Med
2003;139(4):258-66.
·
Haney M,
Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV(+) marijuana
smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl)
2005;181(1):170-8.
·
Haney M,
Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol
and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and
sleep. J Acquir Immune Defic Syndr
2007;45(5):545-54.
·
Bedi G, Foltin RW, Gunderson EW, Rabkin J,
Hart CL, Comer SD, Vosburg SK, Haney M. Efficacy and tolerability of high-dose
dronabinol maintenance in HIV-positive marijuana smokers: a controlled
laboratory study. Psychopharmacology (Berl) 2010;212(4):675-86.
·
Haney M,
Rabkin J, Gunderson E, Foltin RW. Dronabinol
and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and
mood. Psychopharmacology (Berl) 2005;181(1):170-8.
·
Haney M,
Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol
and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and
sleep. J Acquir Immune Defic Syndr
2007;45(5):545-54.
·
Gorter R,
Seefried M, Volberding P. Dronabinol effects on weight in patients with HIV
infection. AIDS 1992;6:127.
·
Plasse
TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical
experience with dronabinol. Pharmacology, Biochemistry and Behavior
1991;40:695-700.
·
Plasse T,
Conant M, Gorter R, Shepard KV. Dronabinol stimulates appetite and causes
weight gain in HIV patients. International Conference on AIDS 1992;8(3):122
(abstract no. PuB 7442).
·
Struwe M,
Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K, Evans TG.
Effect of dronabinol on nutritional status in HIV infection. Annals of
Pharmacotherapy 1993;27:827-831.
·
Beal JE,
Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R,
Powderly W, Plasse TF, Mosdell KW, Shepard KV. Long-term efficacy and safety of
dronabinol for acquired immunodeficiency syndrome-associated anorexia. Journal
of Pain and Symptom Management 1997;14(1):7-14.
·
Dejesus
E, Rodwick BM, Bowers D, Cohen CJ, Pearce D. Use of dronabinol improves
appetite and reverses weight loss in HIV/AIDS-infected patients. J Int Assoc
Physicians AIDS Care 2007;6(2):95-100.
·
Prentiss D, Power R, Balmas G, Tzuang G,
Israelski DM. Patterns of marijuana
use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr 2004;35(1):38-45.
·
Woolridge
E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV
for pain and other medical symptoms. J Pain Symptom Manage 2005;29(4):358-67.
·
Sidney S.
Marijuana use in HIV-positive and AIDS patients: Results of a an anonymous mail
survey. J Cannabis Ther 2001;1(3-4):35-43.
·
Corless
IB, Lindgren T, Holzemer W, Robinson L, Moezzi S, Kirksey K, Coleman C, Tsai
YF, Sanzero Eller L, Hamilton MJ, Sefcik EF, Canaval GE, Rivero Mendez M,
Kemppainen JK, Bunch EH, Nicholas PK, Nokes KM, Dole P, Reynolds N. Marijuana
Effectiveness as an HIV Self-Care Strategy. Clin Nurs Res 2009;18(2):172-93.
·
Jatoi A,
Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S,
Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol versus
megestrol acetate versus combination therapy for cancer-associated anorexia: a
North Central Cancer Treatment Group study. Journal of Clinical Oncology
2002;20(2):567-573.
·
Regelson W, Butler JR, Schulz J, Kirk T, Peek
L, Green ML, Zalis MO. Delta-9-tetrahydrocannabinol
as an effective antidepressant and appetite-stimulating agent in advanced
cancer patients. In: Braude MC, Szara S, editors. Pharmacology of marihuana.
Vol 2. New York: Raven Press, 1976. p. 763-776.
·
Wadleigh
R, Spaulding GM, Lumbersky B, Zimmer M, Shepard K, Plasse T. Dronabinol
enhancement of appetite in cancer patients. Proc Am Soc Oncology 1990; 9: 331.
o
Strasser
F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle
M, Reif M, Cerny T. Comparison of orally administered cannabis extract and
delta-9-tetrahydrocannabinol in treating patients with cancer-related
anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind,
placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group. J Clin Oncol 2006;24(21):3394-400.
·
Brisbois TD,
de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, Macdonald N,
Baracos VE, Wismer WV. Delta-9-tetrahydrocannabinol
may palliate altered chemosensory perception in cancer patients: results of a
randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011 Feb 22.
o
Strasser
F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle
M, Reif M, Cerny T. Comparison of orally administered cannabis extract and
delta-9-tetrahydrocannabinol in treating patients with cancer-related
anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind,
placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group. J Clin Oncol 2006;24(21):3394-400.
·
Plasse
TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical
experience with dronabinol. Pharmacology, Biochemistry and Behavior
1991;40:695-700.
·
Nelson K,
Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol
for appetite stimulation in cancer-associated anorexia. Journal of Palliative
Care 1994;10:14-18.
·
Gottschling
S. [Cannabinoids in children] [Article en allemand] Cannabinoide bei Kindern.
Angewandte Schmerztherapie und Palliativmedizin 2011;(1):55-57.
·
Volicer
L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on
anorexia and disturbed behavior in patients with Alzheimer's disease.
International Journal of Geriatric Psychiatry 1997;12:913-919.
·
Patel S,
Shua-Haim JR, Pass M. Safety and efficacy of dronabinol in the treatment of
agitation in patients with Alzheimer’s disease with anorexia: A retrospective
chart review. Abstract, 11th International Conference of the IPA, 17-22 August
2003, Chicago.
·
Wilson
MM, Philpot C, Morley JE. Anorexia of aging in long term care: is dronabinol an
effective appetite stimulant? - a pilot study. J Nutr Health Aging
2007;11(2):195-8.
o
Gross H,
Ebert MH, Faden VB, Goldberg SC, Kaye WH, Caine ED, Hawks R, Zinberg N. A
double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa.
Journal of Clinical Psychopharmacology
1983;3(3):165-171.
·
Bergmann
K-C. [Dronabinol, a possible new therapeutic option in patients with COPD and
pulmonal cachexia] [Article in German]. Abstract, 2005 Conference of the German
Society for Pneumology, 17 March 2005, Berlin.
·
Foltin
RW, Fishman MW, Brady JV. Behavioral analysis of marijuana effects on food
intake in humans. Pharmacology, Biochemistry and Behavior 1986;25:577-582.
·
Foltin RW, Fischman MW, Byrne MF. Effects of smoked marijuana on food intake and body weight of humans
living in a residential laboratory. Appetite 1988;11(1):1-14.
o
Killestein J, Hoogervorst EL, Reif M, Kalkers
NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH. Safety, tolerability, and efficacy of orally administered cannabinoids
in MS. Neurology 2002;58(9):1404-7.
·
Petro DJ,
Ellenberger C. Treatment of human spasticity with D9-tetrahydrocannabinol.
Journal of Clinical Pharmacology 1981;(Suppl 21):413S-416S.
·
Ungerleider
JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. D9-THC in the treatment
of spasticity associated with multiple sclerosis. Advances in Alcohol and
Substance Abuse 1987;7:39-50.
·
Zajicek
J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, on behalf of the
UK MS Research Group. Cannabinoids for treatment of spasticity and other
symptoms related to multiple sclerosis (CAMS study): multicentre randomised
placebo-controlled trial. Lancet 2003; 362(9385): 1517-1526.
·
Zajicek
JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ,
Fox PJ, Thompson AJ. Cannabinoids in multiple sclerosis (CAMS) study: safety
and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry
2005;76(12):1664-9.
·
Martyn
CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet
1995;345:579.
·
Vaney C,
Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M,
Reif M. Efficacy of tetrahydrocannabinol in
patients refractory to standard antiemetic therapy.Efficacy, safety and
tolerability of an orally administered cannabis extract in the treatment of
spasticity in patients with multiple sclerosis: a randomized, double-blind,
placebo-controlled, crossover study. Multiple
Sclerosis 2004;10(4):417-24.
·
Wade DT,
Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts
have general or specific effects on symptoms in multiple sclerosis? A
double-blind, randomized, placebo-controlled study on 160 patients. Multiple
Sclerosis 2004;10(4):434-41.
·
Zajicek
J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, on behalf of the
UK MS Research Group. Cannabinoids for treatment of spasticity and other
symptoms related to multiple sclerosis (CAMS study): multicentre randomised
placebo-controlled trial. Lancet 2003; 362(9385): 1517-1526.
·
Zajicek
JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ,
Fox PJ, Thompson AJ. Cannabinoids in multiple sclerosis (CAMS) study: safety
and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry
2005;76(12):1664-9.
·
Wade DT,
Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based
medicine in the treatment of spasticity and other symptoms in multiple
sclerosis. Mult Scler 2006;12(5):639-45.
·
Collin C,
Ambler Z, Kent R, McCalla R. A randomised controlled study of Sativex® in
patients with symptoms of spasticity due to multiple sclerosis. 22nd Congress
of the ECTRIMS, 27-30 September 2006, Madrid, Spain.
·
Collin C,
Davies P, Mutiboko IK, Ratcliffe S, for the Sativex Spasticity in MS Study
Group. Randomized controlled trial of cannabis-based medicine in spasticity
caused by multiple sclerosis. Eur J
Neurology 2007;14(3):290–296.
·
Conte A,
Bettolo CM, Onesti E, Frasca V, Iacovelli E, Gilio F, Giacomelli E, Gabriele M,
Aragona M, Tomassini V, Pantano P, Pozzilli C, Inghilleri M.
Cannabinoid-induced effects on the nociceptive system: a neurophysiological
study in patients with secondary progressive multiple sclerosis. Eur J Pain 2009;13(5):472-7.
o
Centonze
D, Mori F, Koch G, Buttari F, Codecà C, Rossi S, Cencioni MT, Bari M, Fiore S,
Bernardi G, Battistini L, Maccarrone M. Lack of effect of cannabis-based
treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci
2009;30(6):531-4.
·
Novotna
A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C,
Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A,
Montalban X, Klimek A, Davies P; the Sativex Spasticity Study Group. A
randomized, double-blind, placebo-controlled, parallel-group, enriched-design
study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with
refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18(9):1122-1131.
·
Meinck
HM, Schönle PWA, Conrad B. Effect of cannabinoids on spasticity and ataxia in
multiple sclerosis. Journal of Neurology 1989;236:120-122.
v
Greenberg
HS, Werness SAS, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects
of smoking marijuana on balance in patients with multiple sclerosis and normal
volunteers. Clinical Pharmacology and Therapeutics 1994;55:324-328.
·
Deutsch
SI, Rosse RB, Connor JM, Burket JA, Murphy ME, Fox FJ. Current status of
cannabis treatment of multiple sclerosis with an illustrative case presentation
of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana
dependence treated with dronabinol. CNS Spectr 2008;13(5):393-403.
·
Consroe
P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked
cannabis on patients with multiple sclerosis. European Neurology 1997;38:44-48.
·
Page SA, Verhoef MJ, Stebbins RA, Metz LM,
Levy JC. Cannabis use as
described by people with multiple sclerosis. Can J Neurol Sci 2003;30(3):201-5.
·
Chong MS,
Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with
multiple sclerosis. Mult Scler 2006;12(5):646-51.
·
Hanigan
WC, Destree R, Truong XT. The effect of D9-THC on human
spasticity. Clinical Pharmacology and Therapeutics 1986;39:198.
·
Maurer M,
Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic
and analgesic effects in a single case double-blind trial. European Archives of
Psychiatry and Clinical Neuroscience 1990;240:1-4.
·
Hagenbach
U, Luz S, Ghafoor N, Berger JM, Grotenhermen F, Brenneisen R, Mäder M. The
treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal
cord injury. Spinal Cord 2007;45(8):551-62.
·
Pooyania
S, Ethans K, Szturm T, Casey A, Perry D. A randomized, double-blinded,
crossover pilot study assessing the effect of nabilone on spasticity in persons
with spinal cord injury. Arch Phys Med Rehabil 2010;91(5):703-7.
·
Kogel RW,
Johnson PB, Chintam R, Robinson CJ, Nemchausky BA. Treatment of spasticity in
spinal cord injury with dronabinol, a tetrahydrocannabinol derivative. American
Journal of Therapeutics 1995;2(10):799-805.
·
Malec J,
Harvey RF, Cayner JJ. Cannabis
effect on spasticity in spinal cord injury. Archives of Physical Medicine and
Rehabilitation 1982;63:116-118.
·
Consroe
P, Tillery W, Rein J, Musty RE. Reported Marijuana effects in patients with spinal
cord injury. 1998 Symposium on the Cannabinoids. Burlington: International
Cannabinoid Research Society, 1998, p. 64.
·
Dunn M,
Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia
1974;12:175.
·
Wade DT,
Robson P, House H, Makela P, Aram J. A preliminary controlled study to
determine whether whole-plant cannabis extracts can improve intractable
neurogenic symptoms. Clinical Rehabilition 2003;17:18-26.
·
Brenneisen
R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally
administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2
patients. International Journal of Clinical Pharmacology and Therapeutics
1996;34:446-452.
·
Lorenz R.
A casuistic rationale for the treatment of spastic and myocloni in a childhood
neurodegenerative disease: neuronal ceroid lipofuscinosis of the type
Jansky-Bielschowsky. Neuro Endocrinol Lett
2002;23(5-6):387-90.
·
Gottschling
S. [Cannabinoids in children] [Article en allemand] Cannabinoide bei Kindern.
Angewandte Schmerztherapie und Palliativmedizin 2011;(1):55-57.
·
Petro DJ.
Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980;21:81-85.
·
Randall RC,
ed. Muscle Spasm, Pain & Marijuana
Therapy. Washington, DC: Galen Press, 1991.
·
Schweizer A,
Bircher HP. Reposition of a dislocated shoulder under use of cannabis.
Wilderness Environ Med 2009;20(3):301-2.
·
Brenneisen
R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally
administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2
patients. International Journal of Clinical Pharmacology and Therapeutics
1996;34:446-452.
·
Maurer M,
Henn V, Dittrich A, Hofmann A. Delta-9-THC shows antispastic and analgesic
effects in a single case double blind trial. European Archives of Psychiatry
and Clinical Neuroscience 1990;240:1-4.
·
Wade DT,
Robson P, House H, Makela P, Aram J. A preliminary controlled study to
determine whether whole-plant cannabis extracts can improve intractable
neurogenic symptoms. Clinical Rehabilitation 2003;17:18-26.
·
Berman
JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for
relief of central neuropathic pain from brachial plexus avulsion: results of a
randomised controlled trial. Pain 2004;112(3):299-306.
·
Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple
sclerosis? Randomised double blind placebo controlled crossover trial. BMJ
2004;329(7460):253.
o
Rintala
DH, Fiess RN, Tan G, Holmes SA, Bruel BM. Effect of dronabinol on central
neuropathic pain after spinal cord injury: a pilot study. Am J Phys Med Rehabil
2010;89(10):840-8.
·
Wissel J, Haydn T, Müller J, Brenneis C,
Berger T, Poewe W, Schelosky LD. Low dose
treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled
cross-over trial. J Neurol 2006;253(10):1337-41.
o
Frank B,
Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and
patient tolerability of nabilone and dihydrocodeine for chronic neuropathic
pain: randomised, crossover, double blind
study. BMJ 2008;336(7637):199-201.
·
Wade DT,
Robson P, House H, Makela P, Aram J. A preliminary controlled study to
determine whether whole-plant cannabis extracts can improve intractable
neurogenic symptoms. Clinical Rehabilitation 2003;17:18-26.
·
Berman J,
Lee J, Cooper M, Cannon A, Sach J, McKerral S, Taggart M, Symonds C, Fishel K,
Birch R. Efficacy of two cannabis-based medicinal extracts for relief of
central neuropathic pain from brachial plexus avulsion: results of a randomised
controlled trial. Anaesthesia, 2003;58:938.
·
Rog DJ,
Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based
medicine in central pain in multiple sclerosis. Neurology 2005;65(6):812-9.
o
Ernst G,
Denke C, Reif M, Schnelle M, Hagmeister H. Standardized cannabis extract in the
treatment of postherpetic neuralgia: a randomized, double-blind,
placebo-controlled cross-over study. IACM 3rd Conference on Cannabinoids in
Medicine, 9-10 September 2005, Leiden, International Association for Cannabis
as Medicine.
·
Nurmikko
TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex
successfully treats neuropathic pain characterised by allodynia: a randomised,
double-blind, placebo-controlled clinical trial. Pain 2007;133(1-3):210-20.
·
Selvarajah
D, Gandhi R, Emery CJ, Tesfaye S. Randomised Placebo Controlled Double Blind
Clinical Trial of Cannabis Based Medicinal Product (Sativex) in Painful
Diabetic Neuropathy: Depression is a Major Confounding Factor. Diabetes Care 2010;33(1):128-30.
·
Abrams
DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC,
Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: A
randomized placebo-controlled trial. Neurology 2007;68(7):515-21.
·
Wilsey B,
Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A
randomized, placebo-controlled, crossover trial of cannabis cigarettes in
neuropathic pain. J Pain 2008;9(6):506-21.
·
Ellis RJ,
Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H,
Atkinson JH. Smoked medicinal cannabis for neuropathic pain in HIV: a
randomized, crossover clinical trial. Neuropsychopharmacology
2009;34(3):672-680.
·
Ware MA,
Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP. Smoked cannabis for chronic
neuropathic pain: a randomized controlled trial. CMAJ 2010;182(14):E694-701.
o
Lindstrom
P, Lindblom U, Boreus L. Lack of effect of cannabidiol in sustained
neuropathia. Paper presented at '87 International Conference on Cannabis,
Melbourne, September 2-4, 1987. Cited from: Consroe P, Sandyk R. Potential role
of cannabinoids for therapy of neurological disorders. In: Murphy L, Bartke A, eds. Marijuana/Cannabinoids. Neurobiology and
Neurophysiology. Boca Raton, CRC Press, 1992:459-524.
·
Karst M,
Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the
synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled
trial. JAMA 2003;290(13):1757-62.
o
Clermont-Gnamien
S, Atlani S, Attal N, Le Mercier F, Guirimand F, Brasseur L. [The therapeutic
use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain]
[Article in French] Presse Med 2002;31(39 Pt 1):1840-5.
·
Finnegan-Ling
D, Musty RE. Marinol and phantom limb pain; a case study. In: 1994 Symposium on
the Cannabinoids. Burlington, Vermont: International Cannabinoid Research
Society, p. 53.
o
Attal N,
Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D. Are oral
cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 2004;8:173–177.
·
Rog DJ,
Nurmikko TJ, Young CA. Oromucosal delta-9-tetrahydrocannabinol/cannabidiol for
neuropathic pain associated with multiple sclerosis: an uncontrolled,
open-label, 2-year extension trial. Clin Ther
2007;29(9):2068-79.
·
Toth C,
Au S. A prospective identification of neuropathic pain in specific chronic
polyneuropathy syndromes and response to pharmacological therapy. Pain
2008;138(3):657-66.
·
Bestard
JA, Toth CC. An Open-Label Comparison of Nabilone and Gabapentin as Adjuvant
Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with
Peripheral Neuropathy. Pain Pract
2011;11(4):353-68.
·
Dunn M, Davis R. The perceived effects of
marijuana on spinal cord injured males. Paraplegia 1974;12:175.
·
Consroe P, Musty R, Rein J, Tillery W,
Pertwee R. The perceived effects of smoked cannabis on patients with multiple
sclerosis. European Neurology 1997;38:44-48.
·
Petro DJ.
Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980;21:81-85.
·
Page SA,
Verhoef MJ, Stebbins RA, Metz LM, Levy JC. Cannabis use as described by people with multiple sclerosis. Can J
Neurol Sci 2003;30(3):201-5.
·
Prentiss D, Power R, Balmas G, Tzuang G,
Israelski DM. Patterns of marijuana
use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr 2004;35(1):38-45.
·
Woolridge
E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV
for pain and other medical symptoms. J Pain Symptom Manage 2005;29(4):358-67.
·
Chong MS,
Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple
sclerosis. Mult Scler 2006;12(5):646-51.
·
Noyes R,
Brunk SF, Baram DA, Canter A. Analgesic effects of delta-9-THC. Journal of
Clinical Pharmacology 1975;15:139-143.
·
Noyes R, Brunk
ST, Avery DH, Canter A. The analgesic properties of
delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology and
Therapeutics 1975;18:84-89.
o Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R,
Fallon MT. Multicenter, Double-Blind, Randomized, Placebo-Controlled,
Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD
Extract and THC Extract in Patients With Intractable Cancer-Related Pain. J
Pain Symptom Manage 2010;39(2):167-79.
·
Johnson
JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT.
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study
of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in
Patients With Intractable Cancer-Related Pain. J Pain Symptom Manage
2010;39(2):167-79.
o
Jochimsen
PR, Lawton RL, VerSteeg K, Noyes Jr R. Effect of benzopyranoperidine, a
delta-9-THC congener, on pain. Clinical Pharmacology and Therapeutics
1978;24:223-7.
·
Staquet
M, Gantt C, Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on
cancer pain. Clinical Pharmacology
and Therapeutics 1978;23:397-401.
·
Butler
JR Peek LA Regelson W
Moore MM Lubin LA. Treatment
effects of delta-9-THC in an advanced cancer population. In: Cohen S, Stillman
RC, eds. The therapeutic potential of marihuana. Plenum Medical Book, New York
1976.
·
Maida V.
The synthetic cannabinoid nabilone improves pain and symptom management in
cancer patients. Abstract of San Antonio Breast Cancer Symposium, 15 December
2006.
·
Maida V, Ennis
M, Irani S, Corbo M, Dolzhykov M. Adjunctive nabilone in cancer pain and
symptom management: a prospective observational study using propensity scoring.
J Support Oncol 2008;6(3):119-24.
·
Blake DR,
Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy,
tolerability and safety of a cannabis-based medicine (Sativex) in the treatment
of pain caused by rheumatoid arthritis. Rheumatology (Oxford)
2006;45(1):50-2.
·
Skrabek
RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in
fibromyalgia. J Pain 2008;9(2):164-73.
·
Ware MA,
Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia:
results of a randomized controlled trial. Anesth Analg 2010;110(2):604-10.
·
Schley M,
Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R. Delta-9-THC based
monotherapy in fibromyalgia patients on experimentally induced pain, axon
reflex flare, and pain relief. Curr Med Res Opin 2006;22(7):1269-1276.
·
Fiz J,
Durán M, Capellà D, Carbonell J, Farré M. Cannabis use in patients with
fibromyalgia: effect on symptoms relief and health-related quality of life.
PLoS One 2011;6(4):e18440.
·
Fiz J, Duran M, Langohr K, Capellà D,
Farré M. Symptoms relief and improved mental health in fibromyalgia patients
using cannabis. Results of an observational study. IACM 4th Conference on
Cannabinoids in Medicine, 5-6 October 2007, Cologne, International Association
for Cannabis as Medicine.
·
Notcutt
W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C. Initial
experiences with medicinal extracts of cannabis for chronic pain: results from
34 'N of 1' studies. Anaesthesia 2004;59(5):440-52.
·
Narang S,
Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN. Efficacy of
dronabinol as an adjuvant treatment for chronic pain patients on opioid
therapy. J Pain 2008;9(3):254-64.
·
Holdcroft
A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M, Evans F. Pain relief with
oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997;52:483-488.
·
Notcutt
W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C. Initial
experiences with medicinal extracts of cannabis for chronic pain: results from
34 'N of 1' studies. Anaesthesia 2004;59(5):440-52.
·
Ware MA,
Ducruet T, Robinson AR. Evaluation
of herbal cannabis characteristics by medical users: a randomized trial. Harm
Reduct J 2006;3(1):32
·
Pinsger
M, Schimetta W, Volc D, Hiermann E, Riederer F, Polz W. [Benefits of an add-on
treatment with the synthetic cannabinomimetic nabilone on patients with chronic
pain - a randomized controlled trial.] [Artikel in deutsch] Wien Klin
Wochenschr 2006;118(11-12):327-35.
·
Phan NQ,
Siepmann D, Gralow I, Ständer S. Adjuvant topical therapy with a cannabinoid
receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges
2010;8(2):88-91.
·
Haroutiunian
S, Rosen G, Shouval R, Davidson E. Open-label, add-on study of
tetrahydrocannabinol for chronic nonmalignant pain. J Pain Palliat Care
Pharmacother 2008;22(3):213-7.
·
Hamann W, di
Vadi PP. Analgesic effect of
the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 1999;353(9152):560.
·
Elsner F, Radbruch L, Sabatowski R.
[Tetrahydrocannabinol for treatment of chronic pain] [Article in German]. Schmerz 2001;15(3):200-4.
·
Noyes R, Baram DA. Cannabis analgesia. Comprehensive Psychiatry 1974:15:531-535.
·
Ware MA, Doyle CR, Woods R, Lynch ME,
Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective
survey. Pain 2003;102(1-2):211-216.
·
Lynch ME, Clark AJ. Cannabis reduces
opioid dose in the treatment of chronic non-cancer pain. J Pain Symptom Manage
2003;25(6):496-8.
·
Howard J,
Anie KA, Holdcroft A, Korn S, Davies SC. Cannabis use in sickle cell disease: a
questionnaire study. Br J Haematol 2005;131(1):123-8.
·
Russo EB,
Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, et al. Chronic cannabis
use in the Compassionate Investigational New Drug Program: An examination of
benefits and adverse effects of legal clinical cannabis. J Cannabis Ther
2002;2(1):3-57.
·
Aggarwal
SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Characteristics
of patients with chronic pain accessing treatment with medical cannabis in
Washington State. J Opioid Manag 2009;5(5):257-86.
o
Raft D,
Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on
experimental and surgical pain: psychological correlates of the analgesic
response. Clinical Pharmacology and Therapeutics 1977;21:26-33.
o
Buggy DJ,
Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic
efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain
2003;106(1-2):169-72.
o
Seeling
W, Kneer L, Buchele B, Gschwend JE, Maier L, Nett C, Simmet T, Steffen P, Schneider
M, Rockemann M. [(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically
in postoperative pain.] [Article in
German]. Anaesthesist
2006;55(4):391-400.
·
Holdcroft
A, Maze M, Dore C, Tebbs S, Thompson S. A multicenter dose-escalation study of
the analgesic and adverse effects of an oral cannabis extract (Cannador) for
postoperative pain management. Anesthesiology 2006;104(5):1040-1046.
o
Beaulieu
P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J
Anaesth 2006;53(8):769-75.
·
Jain AK,
Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and
placebo in acute postoperative pain. Journal
of Clinical Pharmacology 1981;21(suppl 8-9):S320-S326.
·
Kantor
TG, Hopper M. A study of levonantradol, a cannabinol derivative, for analgesia
in post operative pain. Pain
1981; (suppl): S37.
o
Ostenfeld
T, Price J, Albanese M, Bullman J, Guillard F, Meyer I, Leeson R, Costantin C,
Ziviani L, Nocini PF, Milleri S. A randomized, controlled study to investigate
the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166,
ibuprofen or placebo in patients with acute pain following third molar tooth
extraction. Clin J Pain 2011;27(8):668-76.
o
Naef M,
Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The
analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a
THC-morphine combination in healthy subjects under experimental pain
conditions. Pain 2003;105(1-2):79-88.
·
Roberts
JD, Gennings C, Shih M. Synergistic affective analgesic interaction between
delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006;530(1-2):54-8.
o
Redmond
WJ, Goffaux P, Potvin S, Marchand S.
Analgesic and antihyperalgesic effects of nabilone on experimental heat
pain. Curr Med Res Opin
2008;24(4):1017-24.
·
Greenwald MK, Stitzer ML Antinociceptive, subjective and behavioral
effects of smoked marijuana in humans. Drug Alcohol Depend 2000;59(3):261-75.
·
Wallace
M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B,
Abramson I. Dose-dependent effects of smoked cannabis on capsaicin-induced pain
and hyperalgesia in healthy volunteers. Anesthesiology
2007;107(5):785-796.
o
Kraft B, Frickey NA, Kaufmann RM, Reif M,
Frey R, Gustorff B, Kress HG. Lack of
analgesia by oral standardized cannabis extract on acute inflammatory pain and
hyperalgesia in volunteers. Anesthesiology 2008;109(1):101-10.
o
Hill SY,
Schwin R, Goodwin DW, Powell B. Marihuana and pain. J Pharmacol Exp Ther
1974;188:415-8.
o
Clark WC,
Janal MN, Zeidenberg P, Nahas GG. Effects of moderate and high doses of
marihuana on thermal pain: a sensory decision theory analysis. J Clin Pharmacol
1981;21(8-9 Suppl):299S-310S.
·
Raby WN, Modica PA, Wolintz RJ, Murtaugh
K. Dronabinol reduces signs and symptoms of idiopathic intracranial
hypertension: a case report. J Ocul Pharmacol Ther 2006;22(1):68-75.
·
Robbins MS, Tarshish S, Solomon S,
Grosberg BM. Cluster Attacks Responsive to Recreational Cannabis and
Dronabinol. Headache 2009;49(6):914-6.
·
Raby WN, Modica PA, Wolintz RJ, Murtaugh
K. Dronabinol reduces signs and symptoms of idiopathic intracranial
hypertension: a case report. J Ocul Pharmacol Ther 2006;22(1):68-75.
·
Robbins MS, Tarshish S, Solomon S,
Grosberg BM. Cluster Attacks Responsive to Recreational Cannabis and
Dronabinol. Headache 2009;49(6):914-6.
·
Russo EB. Hemp for headache: An in-depth
historical and scientific review of cannabis in migraine treatment. J Cannabis
Ther 2001;1(2):21-92.
o
Weber M,
Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic
lateral sclerosis: a randomised, double-blind crossover trial. J Neurol
Neurosurg Psychiatry 2010;81(10):1135-40.
·
Carter
GT, Rosen BS. Marijuana in the management of amyotrophic lateral sclerosis. Am
J Hosp Palliat Care 2001;18(4):264-70.
·
Amtmann D, Weydt P, Johnson KL, Jensen MP,
Carter GT. Survey of cannabis
use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care
2004;21(2):95-104.
·
Hagenbach
U, Ghafoor N, Brenneisen R, Luz S, Mäder M. Clinical investigation of D-9-tetrahydrocannabinol (THC) as an alternative therapy for overactive
bladders in spinal cord injury (SCI) patients? Abstract, 2001 Congress on
Cannabis and the Cannabinoids, International Association for Cannabis as
Medicine, 25-27 October 2001, Cologne, Germany.
·
Freeman
RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect
of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled
trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17(6):636-41.
·
Brady CM,
DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot
study of cannabis-based extracts for bladder dysfunction in advanced multiple
sclerosis. Multiple Sclerosis 2004;10(4):425-33.
·
de Ridder
D, Constantinescu CS,Fowler C, Kavia R, Sarantis N. Randomised controlled study
of cannabis-based medicine (Sativex®) in patients suffering from multiple
sclerosis associated detrusor overactivity. 22nd Congress of the ECTRIMS, 27-30
September 2006, Madrid, Spain.
·
Freeman
RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect
of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled
trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17(6):636-41.
·
Kavia RB, De Ridder D, Constantinescu CS,
Stott CG, Fowler CJ. Randomized controlled trial of Sativex to treat detrusor
overactivity in multiple sclerosis. Mult Scler 2010;16(11):1349-59.
·
Beaumont
H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens GE. Effect of
Delta(9)-tetrahydrocannabinol, a cannabinoid receptor agonist, on the
triggering of transient lower oesophageal sphincter relaxations in dogs and
humans. Br J Pharmacol 2009;156(1):153-62.
·
Esfandyari
T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory
functions in humans: a randomized,
placebo-controlled study. Am J Physiol Gastrointest Liver Physiol
2007;293(1):G137-45.
o
Klooker TK, Leliefeld KE, Van Den Wijngaard
RM, Boeckxstaens GE. The
cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect
visceral sensitivity to rectal distension in healthy volunteers and IBS
patients. Neurogastroenterol Motil 2011;23(1):30-5, e2.
·
Wong BS,
Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, Zinsmeister AR.
Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility
in Patients with Non-Constipated Irritable Bowel Syndrome. Gastroenterology,
28. Juli 2011 [im Druck]
·
Lal S,
Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H. Cannabis use
amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol
2011;23(10):891-6.
·
Naftali T,
Lev LB, Yablekovitz D, Half E, Konikoff FM. Treatment of Crohn's disease with
cannabis: an observational study. Isr Med Assoc J 2011;13(8):455-8.
·
Lal S,
Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H. Cannabis use
amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011;23(10):891-6.
·
Russo E.
Cannabis treatments in obstetrics and gynecology: A historical review. J
Cannabis Ther 2002;2(3-4):5-35.
·
Clifford
DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Annals of Neurology
1983;13:669-671.
o Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis
on tremor in patients with multiple sclerosis. Neurology 2004;62(7):1105-9.
o
Fox SH,
Kellett M, Moore AP, Crossman AR, Brotchie JM. Randomised, double-blind,
placebo-controlled trial to assess the potential of cannabinoid receptor
stimulation in the treatment of dystonia. Movement Disorders
2002;17(1):145-149.
·
Snider
SR, Consroe P. Treatment of Meige's syndrome with cannabidiol. Neurology
1984;34(Suppl):147.
·
Sandyk R,
Snider SR, Consroe P, Elias SM. Cannabidiol in dystonic movement disorders.
Psychiatry Research 1986;18:291.
·
Consroe
P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic
movement disorders. International Journal of Neuroscience
1986;30:277-282.
·
Sieradzan KA, Fox SH, Dick J, Brotchie JM. The effects of the cannabinoid receptor agonist nabilone on L-DOPA
induced dyskinesia in patients with idiopathic Parkinson's disease (PD). Movement
Disorders 1998;13(Suppl 2):29.
·
Beckmann
Y, Seçil Y, Güngör B, Yiğit T. Tardive Dystonia and the Use of Cannabis.
Turk Psikiyatri Derg 2010;21(1):90-91.
·
Beckmann
Y, Seçil Y, Güngör B, Yiğit T. Tardive Dystonia and the Use of Cannabis.
Turk Psikiyatri Derg 2010;21(1):90-91.
·
Gilson I,
Busalacchi M. Marijuana for intractable hiccups. Lancet 1998; 351(9098): 267.
·
Müller-Vahl KR, Schneider U, Koblenz A,
Jobges M, Kolbe H, Daldrup T, Emrich HM. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol
(THC): a randomized crossover trial. Pharmacopsychiatry 2002;35(2):57-61.
·
Müller-Vahl KR, Schneider U, Prevedel H,
Theloe K, Kolbe H, Daldrup T, Emrich HM. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics
in Tourette syndrome: a 6-week randomized trial. Journal of Clinical
Psychiatry. 2003;64(4):459-65.
·
Müller-Vahl KR, Schneider U, Kolbe H, Emrich
HM. Treatment of Tourette-Syndrome with
delta-9-Tetrahydrocannabinol. American Journal of Psychiatry 1999;156:495.
·
Deutsch
SI, Rosse RB, Connor JM, Burket JA, Murphy ME, Fox FJ. Current status of
cannabis treatment of multiple sclerosis with an illustrative case presentation
of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana
dependence treated with dronabinol. CNS Spectr 2008;13(5):393-403.
·
Müller-Vahl KR, Schneider U, Emrich HM. Combined treatment of Tourette syndrome with delta-9-THC and dopamine
receptor agonists. J Cannabis Ther 2002;2(3-4):145-54.
·
Hasan A,
Rothenberger A, Münchau A, Wobrock T, Falkai P, Roessner V. Oral
delta9-tetrahydrocannabinol improved refractory gilles de la tourette syndrome
in an adolescent by increasing intracortical inhibition: a case report. J Clin
Psychopharmacol 2010;30(2):190-2.
·
Brunnauer A, Segmiller FM, Volkamer T,
Laux G, Müller N, Dehning S. Cannabinoids improve driving ability in a
Tourette's patient. Psychiatry
Res, 9. Juni 2011
·
Müller-Vahl KR, Kolbe H, Schneider U, Emrich
HM. Cannabinoids: Possible role in pathophysiology
of Gilles de la Tourette-syndrome. Acta
Psychiatrica Scandinavica 1998;97:1-5.
·
Sandyk R,
Awerbuch G. Marijuana and Tourette's Syndrome. Journal of Clinical
Psychopharmacology 1988;8:444-445.
·
Hemming
M, Yellowlees PM. Effective treatment of Tourette's syndrome with marijuana. J
Psychopharmacol 1993; 7: 389-91.
·
Farooq
MU, Ducommun E, Goudreau J. Treatment of a hyperkinetic movement disorder
during pregnancy with dronabinol. Parkinsonism Relat Disord 2009;15(3):249-51.
·
Aharonovich
E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E, Nunes EV, Levin FR.
Concurrent cannabis use during treatment for comorbid ADHD and cocaine
dependence: effects on outcome. Am J Drug Alcohol Abuse.
2006;32(4):629-35.
·
Strohbeck-Kuehner
P, Skopp G, Mattern R. [Fitness to drive in spite (because) of THC] [Article in
German]. Arch Kriminol 2007;220(1-2):11-9.
·
Strohbeck-Kuehner
P, Skopp G, Mattern R. [Fitness to drive in spite (because) of THC] [Article in
German]. Arch Kriminol 2007;220(1-2):11-9.
·
O'Connell
TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in
California (2001-2007): demographics, social characteristics, patterns of
cannabis and other drug use of 4117
applicants. Harm Reduct J 2007;4:16.
·
Schindler F, Anghelescu I, Regen F, Jockers-Scherubl
M. Improvement in refractory obsessive compulsive disorder with dronabinol. Am J Psychiatry 2008;165(4):536-7.
·
Grant JE, Odlaug
BL, Chamberlain SR, Kim SW. Dronabinol, a cannabinoid agonist, reduces hair
pulling in trichotillomania: a pilot study. Psychopharmacology (Berl), 19. Mai
2011
o Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox
P, Wright D, Hobart J, Zajicek JP.
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind
crossover study. Neurology 2004;63(7):1245-50.
o
Frankel
JP, Hughes A, Lees AJ, Stern GM. Marijuana for Parkinsonian tremor. Journal of
Neurology, Neurosurgery and Psychiatry 1990;53:436.
o Consroe P, Laguna J, Allender J, Snider S,
Stern L, Sandyk R, Kennedy K, Schram K. Controlled clincal trial of cannabidiol in Huntington's disease.
Pharmacology, Biochemistry and Behavior. 1991;40(3):701-8.
v
Müller-Vahl KR, Schneider U, Emrich HM. Nabilone deteriorates choreatic movements in Huntington`s disease.
Movement Disorders 1999b;14:1038-40.
o
Maas AI, Murray G, Henney H 3rd, Kassem N, Legrand
V, Mangelus M, Muizelaar JP, Stocchetti N, Knoller N; Pharmos TBI
investigators. Efficacy and safety of dexanabinol in severe traumatic brain injury:
results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006;5(1):38-45.
·
Raby WN, Modica PA, Wolintz RJ, Murtaugh
K. Dronabinol reduces signs and symptoms of idiopathic intracranial
hypertension: a case report. J Ocul Pharmacol Ther 2006;22(1):68-75.
·
Szepietowski JC, Szepietowski T, Reich A.
Efficacy and tolerance of the cream containing structured physiological lipids
with endocannabinoids in the treatment of uremic pruritus: a preliminary study.
Acta Dermatovenerol Croat 2005;13(2):97-103.
·
Ständer S,
Reinhardt HW, Luger TA. [Topical cannabinoid agonists: An
effective new possibility for treating chronic pruritus.] [Article in
German]. Hautarzt
2006;57(9):801-7.
·
Neff GW, O'Brien CB, Reddy KR, Bergasa NV,
Regev A, Molina E, Amaro R, Rodriguez
MJ, Chase V, Jeffers L, Schiff E. Preliminary observation with
dronabinol in patients with intractable pruritus secondary to cholestatic liver
disease. Am J
Gastroenterol 2002;97(8):2117-9.
·
Maida V. Nabilone for the treatment of
paraneoplastic night sweats: a report of four cases. J Palliat Med
2008;11(6):929-34.
·
Cunha JM,
Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander
N, Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and
epileptic patients. Pharmacology 1980;21(3):175-85.
·
Consroe PF, Wood GC, Buchsbaum H.
Anticonvulsant nature of marihuana smoking. JAMA 1975;234(3):306-7.
o Ames FR, Cridland S.: Anticonvulsant effect of cannabidiol [letter].
South African Medical Journal 1986;69:14.
o
Trembly
B, Sherman M. Double-blind clinical study of cannabidiol as a secondary
anticonvulsant. Conference on Cannabis and Cannabinoids, Kolympari/Crete, July
1990, cited according to: Consroe P, Sandyk R. Potential role of cannabinoids
for therapy of neurological disorders. In: Murphy L, Bartke A, eds.
Marijuana/Cannabinoids, Neurobiology and Neurophysiology. Boca Raton:
CRC Press 1992, 459-524. [Kommentar: Kein Effekt von Cannabidiol (300 mg/Tag) bei 10 Patienten.]
·
Trembly
B, Sherman M. Double-blind clinical study of cannabidiol as a secondary
anticonvulsant. Conference on Cannabis and Cannabinoids, Kolympari/Crete, July
1990, cited according to: Consroe P, Sandyk R. Potential role of cannabinoids
for therapy of neurological disorders. In: Murphy L, Bartke A, eds.
Marijuana/Cannabinoids, Neurobiology and Neurophysiology. Boca Raton:
CRC Press 1992, 459-524. [Kommentar: Reduzierung der Anfallhäufigkeit mit Cannabidiol (900 - 1200
mg/Tag) bei einem Patienten.]
·
Corral
VL. Differential effects of medical marijuana based on strain and route of
administration: A three-year observational study. J Cannabis Ther
2001;1(3-4):43-59.
·
Mortati K, Dworetzky B, Devinsky O.
Marijuana: an effective antiepileptic treatment in partial epilepsy? A case
report and review of the literature. Rev Neurol Dis 2007;4(2):103-6.
·
Meyniel C, Ollivier Y, Hamidou M, Péréon
Y, Derkinderen P. Dramatic improvement of refractory Isaacs' syndrome after treatment
with dronabinol. Clin Neurol Neurosurg 2011;113(4):323-4.
·
Crawford
WJ, Merritt JC. Effects of
tetrahydrocannabinol on arterial and intraocular hypertension. International
Journal of Clinical Pharmacololgy and Biopharmacy 1979;17(5):191-196.
·
Merritt JC, Crawford WJ, Alexander PC, Anduze
AL, Gelbart SS. Effect of marihuana
on intraocular and blood pressure in glaucoma. Ophthalmology
1980;87(3):222-8.
·
Tomida I,
Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual
application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma
2006;15(5):349-353.
o Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ.
Effect of sublingual application of cannabinoids on intraocular pressure: a
pilot study. J Glaucoma 2006;15(5):349-353.
·
Hepler
RS, Frank IM, Petrus R. Ocular effects of marijuana smoking. In: Braude MC,
Szara S, eds. The pharmacology of marihuana. Raven Press: New York:
1976;815-828.
·
Russo EB,
Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, et al. Chronic cannabis
use in the Compassionate Investigational New Drug Program: An examination of
benefits and adverse effects of legal clinical cannabis. J Cannabis Ther
2002;2(1):3-57.
o
Merritt
JC, Perry DD, Russell DN, Jones BF. Topical delta 9-tetrahydrocannabinol and
aqueous dynamics in glaucoma. Journal of Clinical Pharmacololgy 1981;21(8-9
Suppl):467S-471S.
·
Cooler P,
Gregg JM. Effect of delta-9-tetrahydrocannabinol on intraocular pressure in
humans. Southern Medical Journal 1977;70(8):951-954.
·
Jones RT,
Benowitz N, Herning RI. The clinical relevance of cannabis tolerance and
dependence. Journal of Clinical Pharmacology 1981;21:143S-152S.
o
Levitt M,
Wilson A, Bowman D, Kemel S, Krepart G, Marks V, Schipper H, Thomson G, Weinerman
B, Weinerman R. Physiologic observations in a controlled clinical trial of the
antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in
cancer chemotherapy. Ophthalmologic implications. J Clin Pharmacol 1981;21(8-9
Suppl):103S-109S.
·
Perez-Reyes
M, Wagner D, Wall ME. Davis KH. Intravenous administration of cannabinoids and
intraocular pressure. In: Braude MC, Szara S,
ed. Pharmacology of marihuana. New York: Raven
Press, 1976;829-832.
·
Plange N,
Arend KO, Kaup M, Doehmen B, Adams H, Hendricks S, Cordes A, Huth J, Sponsel
WE, Remky A. Dronabinol and retinal hemodynamics in humans. Am J
Ophthalmol 2007;143(1):173-4.
·
Hepler RS,
Frank IM. Marihuana smoking and intraocular pressure. Journal of the American
Medical Association 1971;217:1392.
·
Flom MC,
Adams AJ, Jones RT. Marijuana smoking and reduced intraocular pressure in human
eye: Drug action or epiphenomenon? Investigative Ophthalmology 1975;14:52-55.
·
Hepler R
S, Frank I M, Petrus R. Ocular effects of marijuana smoking. In: Braude MC,
Szara S, eds. The pharmacology of marihuana. New York: Raven Press,
1976;815-828.
·
Russo EB,
Merzouki A, Molero Mesa J, Frey KA, Bach PJ. Cannabis improves night vision: A pilot study of dark adaptometry and
scotopic sensitivity in kif smokers of the Rif Mountains of Northern Morocco. J
Ethnopharmacol 2004;93(1):99-104.
·
Russo EB,
Merzouki A, Molero Mesa J, Frey KA, Bach PJ. Cannabis improves night vision: A
pilot study of dark adaptometry and scotopic sensitivity in kif smokers of the
Rif Mountains of Northern Morocco. J Ethnopharmacol
2004;93(1):99-104.
·
Tashkin
DP, Reiss S, Shapiro BJ, Calvarese B, Olsen JL, Lodge JW. Bronchial effects of aerosolized delta 9-tetrahydrocannabinol in healthy
and asthmatic subjects. American Review of Respiratory Disease
1977;115(1):57-65.
·
Williams
SJ, Hartley JP, Graham JD. Bronchodilator effect of delta1-tetrahydrocannabinol
administered by aerosol of asthmatic patients. Thorax 1976;31(6):720-723.
·
Tashkin
DP, Shapiro BJ, Lee YE, Harper CE. Effects
of smoked marijuana in experimentally induced asthma. American Review of
Respiratory Disease 1975;112(3):377-386.
·
Vachon L,
Mikus P, Morrissey W, FitzGerald M, Gaensler E. Bronchial effect of marihuana
smoke in asthma. In: Braude MC, Szara
S, eds. The pharmacology of marihuana. Raven Press: New York: 1976;777-784.
o
Gong H
Jr, Tashkin DP, Calvarese B. Comparison of bronchial effects of nabilone and
terbutaline in healthy and asthmatic subjects. Journal of Clinical Pharmacology
1983;23(4):127-133
·
Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol
on specific airway conductance in asthmatic subjects. American Review for Respiratory Diseases. 1974
Apr;109(4):420-8.
·
Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol
on specific airway conductance in asthmatic subjects. American Review for Respiratory Diseases 1974 Apr;109(4):420-8.
·
Gong H
Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. Clinical
Pharmacology and Therapeutics 1984;35(1):26-32.
·
Tashkin
DP, Reiss S, Shapiro BJ, Calvarese B, Olsen JL, Lodge JW. Bronchial effects of
aerosolized delta 9-tetrahydrocannabinol in healthy and asthmatic subjects.
American Review of Respiratory Disease 1977;115(1):57-65.
·
Gong H
Jr, Tashkin DP, Calvarese B. Comparison of bronchial effects of nabilone and
terbutaline in healthy and asthmatic subjects. Journal of Clinical Pharmacology
1983;23(4):127-133.
·
Pickering
EE, Semple SJ, Nazir MS, Murphy K, Snow TM, Cummin AR, Moosavi S, Guz A,
Holdcroft A. Cannabinoid effects on ventilation and breathlessness: A pilot
study of efficacy and safety. Chron Respir Dis 2011;8(2):109-18.
·
Vandrey R,
Umbricht A, Strain EC. Increased Blood Pressure Following Abrupt Cessation of
Daily Cannabis Use. J Addict Med 2011;5(1):16-20.
·
Guzmán M,
Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G,
González-Feria L. A pilot clinical study of Delta9-tetrahydrocannabinol in
patients with recurrent glioblastoma multiforme. Br J Cancer 2006;95(2):197-203.
·
Liang C,
McClean MD, Marsit C, Christensen B, Peters E, Nelson HH, Kelsey KT. A
population-based case-control study of marijuana use and head and neck squamous
cell carcinoma. Cancer Prev Res (Phila Pa) 2009;2(8):759-68.
·
Foroughi
M, Hendson G, Sargent MA, Steinbok P. Spontaneous regression of septum
pellucidum/forniceal pilocytic astrocytomas-possible role of Cannabis
inhalation. Childs Nerv Syst 2011;27(4):671-9.
·
Volicer
L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients
with Alzheimer's disease. International Journal of Geriatric Psychiatry
1997;12:913-919.
·
Patel S,
Shua-Haim JR, Pass M. Safety and efficacy of dronabinol in the treatment of
agitation in patients with Alzheimer’s disease with anorexia: A retrospective
chart review. Abstract, 11th International Conference of the IPA, 17-22 August
2003, Chicago.
·
Ross JS,
Shua-Haim JR. Open-label study of dronabinol in the treatment of refractory
agitation in Alzheimer’s disease: a pilot study. Abstract, ASCP's 34th Annual
Meeting, 12-15 November 2003, San Antonio, USA.
·
Walther
S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime
agitation in severe dementia. Psychopharmacology (Berl) 2006;185(4):524-8.
·
Passmore
MJ. The cannabinoid receptor agonist nabilone for the treatment of
dementia-related agitation. Int J Geriatr Psychiatry 2008;23(1):116-7.
·
Jacobus
J, McQueeny T, Bava S, Schweinsburg BC, Frank LR, Yang TT, Tapert SF. White
matter integrity in adolescents with histories of marijuana use and binge
drinking. Neurotoxicol Teratol 2009;31(6):349-55.
·
Leweke
FM, Koethe D, Gerth CW, Nolden BM, Schreiber D, Hänsel A, Neatby MA, Juelicher
A, Hellmich M, Klosterkötter J. Cannabidiol as an antipsychotic. A double-blind, controlled clinical trial on cannabidiol vs. amisulpride
in acute schizophrenia. IACM 3rd Conference on Cannabinoids in Medicine, 9-10
September 2005, Leiden, International Association for Cannabis as Medicine.
o Zuardi AW, Hallak JE, Dursun SM, Morais SL, Faria Sanches R, Musty RE,
Crippa JA. Cannabidiol monotherapy for treatment-resistant schizophrenia. J
Psychopharmacol 2006;20(5):683-6.
·
Zuardi
AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of cannabidiol.
Journal of Clinical Psychiatry 1995;56:485-486.
·
Schwarcz
G, Karajgi B, McCarthy R. Synthetic delta-9-tetrahydrocannabinol (dronabinol)
can improve the symptoms of schizophrenia. J Clin Psychopharmacol
2009;29(3):255-8.
·
Schwarcz
G, Karajgi B. Improvement in refractory psychosis with dronabinol: four case
reports. J Clin Psychiatry. 2010;71(11):1552-3.
·
Schwarcz
G, Karajgi B, McCarthy R. Synthetic delta-9-tetrahydrocannabinol (dronabinol)
can improve the symptoms of schizophrenia. J Clin Psychopharmacol
2009;29(3):255-8.
·
Schwarcz
G, Karajgi B. Improvement in refractory psychosis with dronabinol: four case
reports. J Clin Psychiatry. 2010;71(11):1552-3.
·
Grinspoon
L, Bakalar JB. The use of cannabis
as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for
clinical research. Journal of Psychoactive Drugs 1998;30(2):171-7.
o El-Mallakh RS, Brown C. The effect of extreme marijuana use on the
long-term course of bipolar I illness: a single case study. J
Psychoactive Drugs 2007;39(2):201-2.
·
Ringen
PA, Vaskinn A, Sundet K, Engh JA, Jónsdóttir H, Simonsen C, Friis S,
Opjordsmoen S, Melle I, Andreassen OA. Opposite relationships between cannabis
use and neurocognitive functioning in bipolar disorder and schizophrenia.
Psychol Med 2010;40(8):1337-47.
·
Regelson W, Butler JR, Schulz J, Kirk T, Peek
L, Green ML, Zalis MO. Delta-9-tetrahydrocannabinol
as an effective antidepressant and appetite-stimulating agent in advanced
cancer patients. In: Braude MC, Szara S, editors. Pharmacology of marihuana.
Vol 2. New York: Raven Press, 1976. p. 763-776.
·
Ware MA,
Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a
nationwide survey. Int J Clin Pract 2005;59(3):291-5.
·
Bergamaschi MM, Queiroz RH, Chagas MH, de
Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N,
Nardi AE, Martín-Santos R, Hallak JE, Zuardi AW, Crippa JA. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in
Treatment-Naïve Social Phobia Patients. Neuropsychopharmacology. 2011 Feb 9.
[Epub ahead of print]
·
Crippa
JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões
MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari
MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JE. Neural basis of anxiolytic
effects of cannabidiol (CBD) in generalized social anxiety disorder: a
preliminary report. J Psychopharmacol 2011;25(1):121-30.
·
Villagonzalo
KA, Dodd S, Ng F, Mihaly S, Langbein A, Berk M. The relationship between
substance use and posttraumatic stress disorder in a methadone maintenance
treatment program. Compr Psychiatry
2011;52(5):562-6.
·
Cornelius
JR, Kirisci L, Reynolds M, Clark DB, Hayes J, Tarter R. PTSD contributes to
teen and young adult cannabis use disorders. Addict Behav 2010;35(2):91-4.
·
Reznik I. Medical cannabis use in
post-traumatic stress disorder: a naturalistic observational study. Abstract
presented at the Cannabinoid Conference 2011, 8-10 September, Bonn, Germany.
·
Mikuriya
TH. Cannabis substitution. An adjunctive therapeutic tool in the treatment of
alcoholism. Medical Times 1970;98(4):187-91.
·
Mikuriya
TH. Cannabis as a substitute for alcohol: a harm-reduction approach. J Cannabis
Ther 2004;4(1):79-93.
·
Reiman A.
Cannabis as a substitute for alcohol and other drugs Harm Reduct J 2009;6:35.
o
Hermann
D, Klages E, Welzel H, Mann K, Croissant B. Low efficacy of non-opioid drugs in
opioid withdrawal symptoms. Addict Biol 2005;10(2):165-9.
·
O'Connell
TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in
California (2001-2007): demographics, social characteristics, patterns of
cannabis and other drug use of 4117
applicants. Harm Reduct J 2007;4:16.
·
Raby WN,
Carpenter KM, Rothenberg J, Brooks AC, Jiang H, Sullivan M, Bisaga A, Comer S,
Nunes EV Intermittent marijuana use is associated with improved retention in
naltrexone treatment for opiate-dependence. Am J Addict 2009;18(4):301-8.
·
Aharonovich
E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E, Nunes EV, Levin FR. Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence:
effects on outcome. Am J Drug Alcohol Abuse. 2006;32(4):629-35.
·
Labigalini E Jr, Rodrigues LR, Da Silveira
DX. Therapeutic use of cannabis by crack
addicts in Brazil. J Psychoactive Drugs 1999;31(4):451-5.
·
Dreher M.
Crack heads and roots daughters: The therapeutic use of cannabis in Jamaica. J
Cannabis Ther 2002;2(3-4):121-33.
·
Haney M, Hart CL, Vosburg SK, Nasser J,
Bennett A, Zubaran C, Foltin RW. Marijuana
withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology
2004;29(1):158-70.
·
Levin FR,
Kleber HD. Use of dronabinol for
cannabis dependence: two case reports and review. Am J Addict 2008;17(2):161-4.
·
Nicholson
AN, Turner C, Stone BM, Robson PJ. Effect of Delta-9-tetrahydrocannabinol and
cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 2004;24(3):305-13.
·
Grinspoon
L, Bakalar JB. Marihuana, the forbidden medicine. Rev. and exp. ed. New Haven:
Yale University Press; 1997.
·
Randall
RC, O'Leary AM. Marijuana Rx: The patients' fight for medicinal pot. New York:
Thunder's Mouth Press; 1998.
·
Corral
VL. Differential effects of medical marijuana based on strain and route of
administration: A three-year observational study. J Cannabis Ther
2001;1(3-4):43-59.
·
Grotenhermen
F, Schnelle M. Survey on the medical use of cannabis and THC in Germany. J
Cannabis Ther 2003;3(2):17-40.
·
Gieringer
D. Medical use of cannabis: Experience in California. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: Pharmacology, toxicology, and therapeutic
potential. Binghamton, NY: Haworth Press; 2001. p. 153-70.
·
Ware MA,
Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a
nationwide survey. Int J Clin Pract 2005;59(3):291-5.
·
Russo EB,
Mathre ML, Byrne A, Velin R, Bach PJ, Sanchez-Ramos J, et al. Chronic cannabis
use in the Compassionate Investigational New Drug Program: An examination of
benefits and adverse effects of legal clinical cannabis. J Cannabis Ther
2002;2(1):3-57.
·
O'Connell
TJ, Bou-Matar CB. Long term marijuana
users seeking medical cannabis in California (2001-2007): demographics, social
characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduct J 2007;4:16.
·
Bottorff
JL, Johnson JL, Moffat BM, Mulvogue T. Relief oriented use of marijuana by teens.
Subst Abuse Treat Prev Policy 2009;4(1):7.